Enclomiphene Citrate vs AndroGel: Combining the Two (Rationale + Risk)

How Each Drug Works

Enclomiphene citrate is the trans-isomer of clomiphene. It blocks estrogen receptors in the hypothalamus and pituitary, removing negative feedback and driving pulsatile release of GnRH, LH, and FSH. Sekhri et al. documented in a 2016 BJU International study (N=71) that enclomiphene 12.5 to 25 mg daily raised mean serum testosterone from 230 ng/dL to 379 ng/dL over 12 weeks while preserving sperm concentrations above 15 million/mL. That matters: the body keeps making its own testosterone through intact Leydig cell stimulation.

AndroGel 1.62% delivers testosterone transdermally. The FDA approved it in 2000. Per the FDA prescribing label, typical starting doses are 20.25 mg/day (two pump actuations), titrated up to 81 mg/day based on morning serum testosterone drawn 2 to 8 hours post-application. Exogenous testosterone feeds back negatively on the pituitary, suppressing LH and FSH within days to weeks.

The Core Mechanistic Conflict

These two drugs work in opposite directions at the pituitary. Enclomiphene tells the gland to produce more gonadotropins. AndroGel tells the gland to produce fewer. Running them simultaneously creates a pharmacological tug-of-war. The net hormonal result depends on the relative doses, individual receptor sensitivity, and baseline HPG-axis tone, none of which are predictable without serial lab monitoring. Research on clomiphene's receptor kinetics confirms that SERM blockade of estrogen receptors can partially override steroid negative feedback, but the partial nature of that blockade means exogenous testosterone at TRT doses can still suppress gonadotropins meaningfully.

Estradiol: The Overlooked Variable

Both drugs alter estradiol. Enclomiphene can raise estradiol by driving aromatization of higher intratesticular testosterone. AndroGel raises estradiol directly through peripheral aromatization of exogenous testosterone. Running both simultaneously may push estradiol above 42 pg/mL, the threshold above which the Endocrine Society Clinical Practice Guideline associates gynecomastia and fluid retention risk. Monitoring serum estradiol (sensitive LC-MS/MS assay) every 6 to 8 weeks is necessary, not optional, when both agents are active.

Clinical Evidence for Each Drug Alone

Enclomiphene Citrate Monotherapy

The Phase 3 data for enclomiphene are largely from Repros Therapeutics trials conducted between 2008 and 2014. A 2013 Andrologia publication reported that enclomiphene 25 mg daily normalized testosterone (>300 ng/dL) in 75% of secondary hypogonadal men at 3 months. Sperm concentrations were preserved or increased in all treatment arms, something no exogenous testosterone product can claim.

Enclomiphene has not received FDA approval for hypogonadism. The FDA issued a Complete Response Letter to Repros in 2014 citing insufficient long-term safety data. Compounding pharmacies supply it under a physician prescription, which means product consistency can vary between batches. FDA guidance on compounded testosterone and SERM products outlines the regulatory limitations clinicians must communicate to patients.

AndroGel in Randomized Trials

The Testosterone Trials (T-Trials), published in the New England Journal of Medicine in 2016 (N=790 men aged 65 and older with testosterone <275 ng/dL), provide the most rigorous dataset for transdermal testosterone. Snyder et al. reported that AndroGel 1% (titrated to testosterone 500 ng/dL) improved sexual function scores by 0.58 points on the PDSS scale (P<0.001 vs. Placebo), increased bone density at the spine (2.0% net gain), and improved walking distance modestly. The cardiovascular signal was not statistically significant in the T-Trials, though the trial was not powered for that outcome.

The 2018 TRAVERSE trial design paper was launched specifically to address cardiovascular safety in men with pre-existing or high-risk cardiovascular disease on TRT. Results published in 2023 found testosterone therapy non-inferior to placebo for major adverse cardiac events over a median 33 months. Lincoff et al. NEJM 2023 reported a MACE rate of 7.0% with testosterone vs. 7.3% with placebo (hazard ratio 0.96, 95% CI 0.78 to 1.17).

Hematocrit elevation remains the most common dose-dependent adverse effect. The Endocrine Society guideline recommends withholding or reducing the testosterone dose if hematocrit exceeds 54%.

The Rationale for Combining Enclomiphene With AndroGel

Fertility Preservation During TRT

The primary clinical reason a physician might add enclomiphene to ongoing AndroGel therapy is fertility preservation. Exogenous testosterone suppresses spermatogenesis in 40 to 90% of men within 3 to 6 months, depending on dose and individual sensitivity. Contraceptive testosterone studies confirm azoospermia or severe oligospermia develops in the majority of men on standard TRT doses within 6 months. A man who wants to conceive but also needs symptomatic testosterone replacement faces a real clinical dilemma.

Adding a gonadotropin stimulator (enclomiphene, or alternatively hCG) is the theoretical solution. By keeping LH and FSH from falling to undetectable levels, intratesticular testosterone remains sufficient for spermatogenesis even while systemic testosterone comes partly from the gel. A 2020 Fertility and Sterility review concluded that combination regimens including SERMs or hCG alongside TRT can maintain sperm production in selected men, though response rates vary and no head-to-head RCT of enclomiphene plus transdermal testosterone has been published.

Testicular Volume Maintenance

Testicular atrophy is a near-universal consequence of long-term TRT monotherapy. Some men place high value on avoiding it. Enclomiphene sustains LH-driven Leydig cell activity and FSH-driven Sertoli cell activity, both of which support testicular architecture. Kim et al. 2016 (BJU Int) measured testicular volume by ultrasound and found no significant reduction in men on enclomiphene at 12 weeks, contrasting with the well-documented atrophy seen with exogenous testosterone. Whether that protective effect persists when competing with the suppressive effects of AndroGel has not been studied in a controlled trial.

Secondary Hypogonadism With Inadequate Monotherapy Response

A smaller subset of men on AndroGel absorb the gel poorly due to skin characteristics, sweating, or application site issues. Adding enclomiphene theoretically supports endogenous production to compensate. This rationale is clinically weak: the more direct fix is optimizing gel application technique, switching to a different delivery system (injections, pellets, nasal gel), or increasing the AndroGel dose within the FDA-approved range. Combining drugs to compensate for suboptimal delivery adds complexity without strong trial evidence.

Risks of the Combination

Estradiol Excess and Gynecomastia

As described in the mechanism section, both drugs drive aromatization. Estradiol above 42 pg/mL increases breast tissue sensitivity. Symptomatic gynecomastia (tender glandular tissue, not just adipose) is reported in 3 to 5% of men on TRT monotherapy; adding a SERM that raises endogenous testosterone production on top of exogenous gel pushes that risk higher. Bhasin et al. Endocrine Society 2018 note that gynecomastia risk rises with estradiol elevation regardless of the mechanism causing it.

Erythrocytosis

Testosterone, from any source, stimulates erythropoietin. Combining two testosterone-elevating mechanisms may produce additive hematocrit elevation. Hematocrit above 54% increases blood viscosity and raises the theoretical risk of venous thromboembolism. FDA-required labeling for all testosterone products carries a boxed warning about secondary exposure and a general warning about polycythemia. Baseline and follow-up hematocrit (at 3 months, then annually if stable) is mandatory in any man on testosterone-raising therapy.

Unpredictable Hormone Levels and Symptom Instability

When two agents with opposing pituitary effects run simultaneously, the resulting testosterone and LH levels can fluctuate outside predictable ranges. Men may report alternating symptoms of excess testosterone (acne, irritability, night sweats) and insufficient testosterone (fatigue, low libido) within the same week. Dose adjustments become difficult because changing one drug shifts the balance of the other. Clinicians managing this combination need testosterone, LH, FSH, and estradiol drawn at a consistent time relative to AndroGel application (2 to 8 hours post-application for peak; trough the next morning for reference range) to interpret results meaningfully. Dobs et al. demonstrated that transdermal testosterone pharmacokinetics vary significantly between individuals, which compounds the unpredictability of a combination regimen.

Transfer Risk With AndroGel

AndroGel carries an FDA black-box warning for secondary exposure in women and children through skin contact. FDA MedWatch data document virilization cases in pediatric contacts. Adding enclomiphene does not reduce this risk; it remains present as long as AndroGel is applied and proper precautions (covering application site, hand washing, avoiding skin contact for several hours) are not followed.

Switching From Enclomiphene Citrate to AndroGel

Why Men Switch

Men typically move from enclomiphene to AndroGel when enclomiphene monotherapy fails to raise testosterone adequately (a common scenario in primary hypogonadism where the testes cannot respond to increased gonadotropin stimulation), when symptom relief is insufficient despite normalized LH and FSH, or when fertility is no longer a treatment priority. A 2019 Urology paper noted that roughly 25% of men on clomiphene-class agents for secondary hypogonadism required escalation to exogenous testosterone within 24 months due to inadequate symptom control.

What to Expect Physiologically

Stopping enclomiphene and starting AndroGel means the HPG axis shifts from stimulated to suppressed within 14 to 28 days. LH and FSH fall to near-zero. Intratesticular testosterone drops even as systemic testosterone rises. Sperm production may begin declining within 6 weeks and can reach severe oligospermia by 3 months. Men who switch and later want to conceive should expect a 6 to 18 month recovery period for spermatogenesis after stopping AndroGel, though recovery is not guaranteed in all men. WHO data on male contraceptive testosterone studies show that 8% of men did not recover adequate sperm counts after 12 months off exogenous testosterone.

Overlap Period Management

A brief overlap (typically 2 to 4 weeks) where enclomiphene is tapered while AndroGel is titrated up can smooth the symptomatic transition. The overlap should be as short as possible. Running both at full dose for more than 4 weeks is not supported by evidence and carries the estradiol and erythrocytosis risks described above. Labs should be drawn at the end of the overlap to confirm suppression of LH and FSH (confirming AndroGel is driving the axis) and adequate testosterone levels before declaring the switch complete.

Patient Selection: Who Should Consider Each Approach

Enclomiphene Is the Better Starting Choice When

The man has confirmed secondary hypogonadism (low testosterone with low or normal LH and FSH, intact testes), wishes to preserve fertility or testicular volume, has no history of thrombophilia or polycythemia, and is willing to accept that FDA approval is absent and pharmacy sourcing requires due diligence. Serum testosterone response should be checked at 6 weeks; if total testosterone remains below 300 ng/dL on 25 mg daily, enclomiphene monotherapy is unlikely to be sufficient and the treatment plan needs reassessment.

AndroGel Is the Better Starting Choice When

The man has primary hypogonadism (Klinefelter syndrome, post-orchitis, post-chemotherapy), has completed his family, is 65 or older (the T-Trials population most studied), or has failed SERM-class therapy. The Endocrine Society 2018 guideline recommends exogenous testosterone as first-line for primary hypogonadism because the testes cannot respond to gonadotropin stimulation regardless of how much LH or FSH is produced.

The Combination Is Rarely the First Choice

A combination regimen is defensible in a narrow window: a man already on TRT who wishes to conceive and whose physician judges that hCG is unavailable or poorly tolerated, and who has baseline testosterone levels that would be subtherapeutic on enclomiphene alone. Outside that window, the combination adds pharmacological complexity, monitoring burden, and cost with limited evidence of net benefit over either agent optimized as monotherapy.

Monitoring Protocol for the Combination Regimen

Any clinician prescribing enclomiphene alongside AndroGel should follow a structured monitoring schedule. At baseline: total testosterone, free testosterone, LH, FSH, estradiol (sensitive assay), hematocrit, PSA (in men over 40), and semen analysis if fertility matters. At 6 and 12 weeks: repeat the full panel plus liver enzymes (enclomiphene is hepatically metabolized). At 6 months: repeat all labs and assess whether the combination is achieving its stated goal (usually fertility preservation plus symptom resolution). If semen analysis shows azoospermia at 3 months despite enclomiphene, the combination is not working for its primary purpose and the regimen should be reconsidered.

The American Urological Association guideline on male infertility recommends semen analysis as a core outcome measure in any treatment affecting the HPG axis. Testosterone level targets should aim for 400 to 700 ng/dL total testosterone when combining agents, staying within the physiologic range to minimize erythrocytosis and cardiovascular risk.

The Endocrine Society states directly: "We recommend against starting testosterone therapy in men who are currently trying to father a child." (Bhasin et al. 2018) That position does not preclude combination regimens in carefully selected patients, but it sets the default expectation that fertility and TRT are usually in tension, not combination.